BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25467141)

  • 1. Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody.
    Kawagashira Y; Koike H; Ohyama K; Hashimoto R; Iijima M; Adachi H; Katsuno M; Chapman M; Lunn M; Sobue G
    J Neurol Sci; 2015 Jan; 348(1-2):67-73. PubMed ID: 25467141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study.
    Iancu Ferfoglia R; Guimarães-Costa R; Viala K; Musset L; Neil J; Marin B; Léger JM
    J Peripher Nerv Syst; 2016 Mar; 21(1):10-4. PubMed ID: 26748872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rapid improvement by rituximab treatment in a case of demyelinating polyneuropathy with anti-myelin-associated glycoprotein antibody].
    Motoyama R; Yamakawa K; Suzuki S; Kusunoki S; Tanaka M
    Rinsho Shinkeigaku; 2011 Oct; 51(10):761-4. PubMed ID: 22019868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.
    Lunn MP; Nobile-Orazio E
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD002827. PubMed ID: 27701752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy.
    Kuijf ML; Eurelings M; Tio-Gillen AP; van Doorn PA; van den Berg LH; Hooijkaas H; Stork J; Notermans NC; Jacobs BC
    Neurology; 2009 Sep; 73(9):688-95. PubMed ID: 19720975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant Expression of Nodal and Paranodal Molecules in Neuropathy Associated With IgM Monoclonal Gammopathy With Anti-Myelin-Associated Glycoprotein Antibodies.
    Kawagashira Y; Koike H; Takahashi M; Ohyama K; Iijima M; Katsuno M; Niwa JI; Doyu M; Sobue G
    J Neuropathol Exp Neurol; 2020 Dec; 79(12):1303-1312. PubMed ID: 32856086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy.
    Briani C; Visentin A; Salvalaggio A; Cacciavillani M; Trentin L
    Eur J Neurol; 2019 Feb; 26(2):371-375. PubMed ID: 30315672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-myelin-associated glycoprotein antibody positive IgM monoclonal gammopathy related peripheral neuropathy: 11 cases and literature review].
    Gao XM; Jia MN; Qian M; Ren HT; Zhang L; Shen KN; Cao XX; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):901-905. PubMed ID: 31856437
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features.
    Svahn J; Petiot P; Antoine JC; Vial C; Delmont E; Viala K; Steck AJ; Magot A; Cauquil C; Zarea A; Echaniz-Laguna A; Iancu Ferfoglia R; Gueguen A; Magy L; Léger JM; Kuntzer T; Ferraud K; Lacour A; Camdessanché JP;
    J Neurol Neurosurg Psychiatry; 2018 May; 89(5):499-505. PubMed ID: 29070644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.
    Dalakas MC; Rakocevic G; Salajegheh M; Dambrosia JM; Hahn AF; Raju R; McElroy B
    Ann Neurol; 2009 Mar; 65(3):286-93. PubMed ID: 19334068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M.
    Benedetti L; Briani C; Grandis M; Vigo T; Gobbi M; Ghiglione E; Carpo M; Cocito D; Caporale CM; Sormani MP; Mancardi GL; Nobile-Orazio E; Schenone A
    J Peripher Nerv Syst; 2007 Jun; 12(2):102-7. PubMed ID: 17565535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of IgM paraproteinemic neuropathy associated with anti-sulfated glucuronic paragloboside (SGPG) IgG antibody without anti-myelin-associated glycoprotein (MAG) activity].
    Nakamura H; Endo M; Sugawara E; Kuwahara M; Kusunoki S; Tanaka F; Takahashi T
    Rinsho Shinkeigaku; 2013; 53(10):799-802. PubMed ID: 24225562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Widening of myelin lamellae in polyneuropathy with immunoglobulin-M monoclonal gammopathy, without activity against myelin-associated glycoprotein, responsive to treatment.
    Vallat JM; Deschamps N; Richard L; Magy L; Devaux J; Mathis S
    Neuromuscul Disord; 2022 Aug; 32(8):678-681. PubMed ID: 35618575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy.
    Sala E; Robert-Varvat F; Paul S; Camdessanché JP; Antoine JC
    J Neurol Sci; 2014 Oct; 345(1-2):224-7. PubMed ID: 25115501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.
    Léger JM; Viala K; Nicolas G; Créange A; Vallat JM; Pouget J; Clavelou P; Vial C; Steck A; Musset L; Marin B;
    Neurology; 2013 Jun; 80(24):2217-25. PubMed ID: 23667063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies.
    Magy L; Kaboré R; Mathis S; Lebeau P; Ghorab K; Caudie C; Vallat JM
    J Immunol Res; 2015; 2015():450391. PubMed ID: 26065001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy.
    Pascual-Goñi E; Martín-Aguilar L; Lleixà C; Martínez-Martínez L; Simón-Talero MJ; Díaz-Manera J; Cortés-Vicente E; Rojas-García R; Moga E; Juárez C; Illa I; Querol L
    Sci Rep; 2019 Apr; 9(1):6155. PubMed ID: 30992531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.
    Lunn MP; Nobile-Orazio E
    Cochrane Database Syst Rev; 2012 May; (5):CD002827. PubMed ID: 22592686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Confocal microscopic localization of anti-myelin-associated glycoprotein autoantibodies in a patient with peripheral neuropathy initially lacking a detectable IgM gammopathy.
    Gabriel JM; Erne B; Bernasconi L; Tosi C; Probst A; Landmann L; Steck AJ
    Acta Neuropathol; 1998 May; 95(5):540-6. PubMed ID: 9600601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy.
    Zara G; Zambello R; Ermani M
    Clin Neurophysiol; 2011 Dec; 122(12):2518-22. PubMed ID: 21680240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.